Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
| Member | Definition | Class |
|---|
| 1-(2-(4-(4-fluoro-benzoyl)-piperidin-1-yl)-ethyl)-3,3-dimethyl-1,2-dihydro-indol-2-one | A hydrochloride resulting from the formal reation of equimolar amount of LY-310762 with hydrogen chloride. A potent and selective antagonist for the 5-hydroxytryptamine 1D (5-HT1D) receptor. | LY-310762 hydrochloride |
| 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine | A hydrobromide obtained by reaction of NAN 190 with one equivalent of hydrobromic acid. | NAN 190 hydrobromide |
| 1-methyl-d-lysergic acid butanolamide | A synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD and used prophylactically to reduce the frequency and intensity of severe vascular headaches. | methysergide |
| 3alpha-hydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | A steroid acid that is ergosta-8,24(28)-dien-26-oic acid substituted by a hydroxy group at position 3, a methyl group at position 4 and oxo groups at positions 7 and 11 (the 3alpha,4alpha,5alpha stereoisomer). Isolated from Antrodia cinnamomea and Antrodia camphorata, it exhibits cytotoxic, anticholinergic and antiserotonergic activities. | zhankuic acid B |
| 8-hydroxy-2-(di-n-propylamino)tetralin | A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively | 8-OH-DPAT |
| alosetron | A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position. | alosetron |
| alosetron hydrochloride | The hydrochloride salt of alosetron. | alosetron hydrochloride |
| amperozide | A member of the class of ureas that is urea in which three of the four hydrogens are replaced by ethyl and 4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl groups. An atypical antipsychotic which was in clinical development for the treatment of schizophrenia and substance-related disorders. It is a potent 5-HT2A antagonist and used in veterinary medicine because of its sedative effect on pigs. | amperozide |
| amperozide hydrochloride | The hydrochloride salt of amperozide. | amperozide hydrochloride |
| brl 15572 | An N-alkylpiperazine that is 1-(3-chlorophenyl)piperazine carrying a 3,3-diphenyl-2-hydroxyprop-1-yl group at position 4. A selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types. | 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol |
| brl 15572 | A hydrochloride that is the monohydrochloride salt of 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol. A selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types. | 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol hydrochloride |
| clomipramine | A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias. | clomipramine |
| clomipramine hydrochloride | A hydrochloride resulting from the reaction of equimolar amounts of clomipramine and hydrogen chloride. One of the more sedating tricyclic antidepressants, it is used for the treatment of depression as well as obsessive-compulsive disorder and phobias. | clomipramine hydrochloride |
| clopenthixol | A thioxanthene derivative having a chloro substituent at the 2-position and an alkylidene group at the 10-position with undefined double bond stereochemistry. | clopenthixol |
| clozapine | A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia. | clozapine |
| cyproheptadine | The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia. | cyproheptadine |
| demethylmirtazapine | A benzazepine metabolite resulting from demethylation of the antidpressant, mirtazapine. | N-demethylmirtazapine |
| dotarizine | An N-alkylpiperazine in which the two amino hydrogens of piperazine have been replaced by diphenylmethyl and 3-(2-phenyl-1,3-dioxolan-2-yl)propyl groups. A calcium channel blocker and serotonin (5-HT2) receptor antagonist used in the treatment of migraine. | dotarizine |
| fk 1052 | An organic heterotricyclic compound that is 8,9-dihydropyrido[1,2-a]indol-6(7H)-one substituted by a (5-methyl-1H-imidazol-4-yl)methyl group at position 7R and a methyl group at position 10. It is a dual 5-HT3 and 5-HT4 receptors antagonist whose clinical development was terminated in phase II. It was being developed for the treatment of chemotherapy-induced emesis and irritable bowel syndrome. | fabesetron |
| flibanserin | An N-alkylpiperazine that is 1-[2-(1,3-dihydro-2-oxobenzimidazol-1-yl)ethyl]piperazine in which the remaining amino proton is replaced by a 3-(trifluoromethyl)phenyl group. A multifunctional serotonin agonist and antagonist which is used for the treatment of pre-menopausal women with hypoactive sexual desire disorder. | flibanserin |
| gr 113808 | An indolyl carboxylate ester obtained by formal condensation between the carboxy group of 1-methylindole-3-carboxylic acid with the hydroxy group of N-{2-[4-(hydroxymethyl)piperidin-1-yl]ethyl}methanesulfonamide. | GR 113808 |
| GR 127935 hydrochloride | A hydrochloride obtained by reaction of GR 127935 with one equivalent of hydrochloric acid. Potent and selective 5-HT1B/1D receptor antagonist (pKi values are 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptors). Displays > 100-fold selectivity over 5HT1A, 5-HT2A, 5-HT2C receptors and other receptor types. Centrally active following oral administration. | GR 127935 hydrochloride |
| gramine | An aminoalkylindole that is indole carrying a dimethylaminomethyl substituent at postion 3. | gramine |
| haloperidol | A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. | haloperidol |
| hp 873 | A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia. | iloperidone |
| ketanserin | A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group. | ketanserin |
| lurasidone | An N-arylpiperazine that is (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-(piperazin-1-ylmethyl)cyclohexyl]methyl}hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione in which position N4 of the piperazine ring is substituted by a 1,2-benzothiazol-3-yl group. Lurasidone is used (generally as the hydrochloride salt) as an atypical antipsychotic for the treatment of schizophrenia. | lurasidone |
| lurasidone hydrochloride | A hydrochloride obtained by reaction of lurasidone with one equivalent of hydrochloric acid. An atypical antipsychotic agent used for the treatment of schizophrenia. | lurasidone hydrochloride |
| ly 367265 | A fluoroindole that is 1H-indole in which the hydrogens at positions 3 and 6 are replaced by 1-[2-(2,2-dioxo-5,6-dihydro-4H-2lambda(6)-[1,2,5]thiadiazolo[4,3,2-ij]quinolin-1(2H)-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl and fluoro groups, respectively. It is an inhibitor of the 5-hydroxytryptamine transporter (Ki = 2.3 nM) and an antagonist of 5-hydroxytryptamine(2A) receptor (Ki = 0.81 nM). | LY-367,265 |
| LY-310762 | A member of the class of oxindoles that is 1-ethyl-3,3-dimethyl-1,3-dihydro-2H-indol-2-one in which the ethyl group has been substituted at position 2 by a 4-(p-fluorobenzoyl)piperidin-1-yl group. It is a potent and selective antagonist for the 5-hydroxytryptamine 1D (5-HT1D) receptor. | LY-310762 |
| mesulergine | A member of the class of ergot alkaloids that is known to act on serotonin and dopamine receptors. | mesulergine |
| metergoline | An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7. | metergoline |
| methiothepin | A dibenzothiepine that is 10,11-dihydrodibenzo[b,f]thiepine bearing additional methylthio and 4-methylpiperazin-1-yl substituents at positions 8 and 10 respectively. Potent 5-HT2 antagonist, also active as 5-HT1 antagonist. Differentiates 5-HT1D sub-types. Also displays affinity for rodent 5-HT5B, 5-HT5A, 5-HT7 and 5-HT6 receptors (pK1 values are 6.6, 7.0, 8.4 and 8.7 respectively). | methiothepin |
| methotrimeprazine | A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively. | methotrimeprazine |
| mianserin | A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere. | mianserin |
| mirtazapine | | mirtazapine |
| n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea | A member of ther class of ureas that is urea in which a hydrogen attached to one of the nitrogens has been replaced by an N-methylindol-5-yl group, while a hydrogen attached to the other nitrogen has been replaced by a 3-methyl-1,2-thiazol-5-yl group. It is a potent and selective antagonist for the 5-hydroxytryptamine 2B (5-HT2B) receptor. | 1-(1-methylindol-5-yl)-3-(3-methyl-1,2-thiazol-5-yl)urea |
| nan 190 | An N-alkylpiperazine that consists of (2-methoxyphenyl)piperazine in which the amine hydrogen is substituted by a 4-(2-phthalimido)butyl group. | NAN 190 |
| nefazodone | | nefazodone |
| norclozapine | A dibenzodoazepine substituted with chloro and piperazino groups which is a major metabolite of clozapine; a potent and selective 5-HT2C serotonin receptor antagonist. | N-desmethylclozapine |
| olanzapine | A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4. | olanzapine |
| oxatomide | A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug. | oxatomide |
| palonosetron | An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. | palonosetron |
| picrotoxinin | A picrotoxane sesquiterpenoid that is 3a,4,5,6,7,7a-hexahydro-1H-indene-3,7-dicarboxylic acid which is substituted at positions 3a, 6, and 7a by methyl, isopropenyl, and hydroxy groups, respectively; in which the double bond at position 2-3 has been epoxidised; and in which the carboxy groups at positions 3 and 7 have undergone gamma-lactone formation by O-alkylation to positions 4 and 5, respectively. A component of picrotoxin. | picrotoxinin |
| pimavanserin | A member of the class of ureas in which three of the four hydrogens are replaced by 4-fluorobenzyl, 1-methylpiperidin-4-yl, and 4-(isopropyloxy)benzyl groups. An atypical antipsychotic that is used (in the form of its tartrate salt) for treatment of hallucinations and delusions associated with Parkinson's disease. | pimavanserin |
| pimozide | A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group. | pimozide |
| pindolol | A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol. | pindolol |
| pipamperone | A member of the class of bipiperidines that is 1,4'-bipiperidine which is substituted at the 1' and 4' positions by 4-(p-fluorophenyl)-4-oxobutyl and carboxamide groups, respectively. A first generation antipsychotic, its properties are generally similar to those of haloperidol. | pipamperone |
| pipamperone dihydrochloride | A hydrochloride resulting from the reaction of pipamperone with 2 mol eq. of hydrogen chloride. It is used as an antipsychotic. | pipamperone dihydrochloride |
| pizotyline | A benzocycloheptathiophene that is 9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophene 4-ylidene)-1-methylpiperidine which is joined from the 4 position to the 4 position of an N-methylpiperidine moiety by a double bond. It is a sedating antihistamine, with strong serotonin antagonist and weak antimuscarinic activity. It is generally used as the malate salt for the treatment of migraine and the prevention of headache attacks during cluster periods. | pizotifen |
| promazine | A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position. | promazine |
| propiomazine | A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 2-(dimethylamino)propyl group at nitrogen atom and a propanoyl group at position 2. | propiomazine |
| quetiapine | | quetiapine |
| risperidone | A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2. | risperidone |
| ritanserin | A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action. | ritanserin |
| rs 25259-197 | A hydrochloride obtained by combining palonosetron with one molar equivalent of hydrogen chloride; an antiemetic used in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. | palonosetron hydrochloride |
| rs 39604 | A hydrochloride salt obtained by mixing equimolar amounts of RS 39604 with hydrochloric acid. A potent and selective 5-HT4 antagonist, with a pKi of 9.1 at 5-HT4 receptors in guinea pig striatal membranes and greater than 1000-fold selectivity over 5-HT1A, 2C, 3 and D1, D2, M1, M2, AT1, B1 and alpha1C receptors. The ketone group gives RS 39604 a relatively long half life; it is also orally active and so suitable for in vivo studies. | RS 39604 hydrochloride |
| sb-224289 | A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid with the secondary amino group of 1'-methyl-6,7-dihydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine]. Selective 5-HT1B receptor antagonist (pKi = 8.2). Displays >60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. Centrally active following oral administration in vivo. | SB 224289 |
| sertindole | A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group. | sertindole |
| setiptiline | A tetracyclic antidepressant that is 2,3,4,9-tetrahydro-1H-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine carrying a methyl group at position 2. Its maleate salt is used for the treatment of depression in Japan. | setiptiline |
| spiperone | An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively. | spiperone |
| spiramide | An azaspiro compound that consists of 1,3,8-triazaspiro[4.5]decan-4-one having a phenyl group attached to N-1 and a 3-(4-fluorophenoxy)propyl attached to N-8. Selective 5-HT antagonist, which binds to 5-HT2 sites as potently as spiperone but has lower affinity for 5-HT2C receptors. Also a high affinity D2 receptor antagonist (Ki = 3 nM). Lacks the disruptive effect of spiperone on animal behaviour. | spiramide |
| thiethylperazine | A member of the class of phenothiazines that is perazine substituted by a ethylsulfanyl group at position 2. | thiethylperazine |
| thioridazine | A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position. | thioridazine |
| tramadol | A 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol in which both stereocentres have R-configuration; the (R,R)-enantiomer of the racemic opioid analgesic tramadol, it exhibits ten-fold higher analgesic potency than the (S,S)-enantiomer. | (R,R)-tramadol |
| tramadol hydrochloride | A hydrochloride resulting from the reaction of (R,R)-tramadol with 1 molar equivalent of hydrogen chloride; the (R,R)-enantiomer of the racemic opioid analgesic tramadol hydrochloride, it exhibits ten-fold higher analgesic potency than the (S,S)-enantiomer. | (R,R)-tramadol hydrochloride |
| vortioxetine | An N-arylpiperazine in which the aryl group is specified as 2-[(2,4-dimethylphenyl)sulfanyl]phenyl. Used (as its hydrobromide salt) for treatment of major depressive disorder. | vortioxetine |
| yohimbine | An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina. | yohimbine |
| ziprasidone | A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms. | ziprasidone |
| zuclopenthixol | The (Z)-isomer of clopenthixol. | zuclopenthixol |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 22.9258 | 1 | 4 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 24.0165 | 1 | 6 |
| 2,3-bisphosphoglycerate-independent phosphoglycerate mutase | Leishmania major strain Friedlin | Potency | 0.0478 | 1 | 1 |
| 67.9K protein | Vaccinia virus | Potency | 31.2162 | 2 | 7 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 27.4377 | 4 | 29 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 25.3397 | 2 | 8 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 27.6115 | 1 | 14 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 19.9369 | 2 | 3 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 13.4270 | 1 | 2 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 32.5874 | 1 | 4 |
| AR protein | Homo sapiens (human) | Potency | 22.5176 | 10 | 132 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 22.9983 | 2 | 14 |
| arylsulfatase A | Homo sapiens (human) | Potency | 12.0521 | 1 | 13 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 18.4755 | 4 | 31 |
| Ataxin-2 | Homo sapiens (human) | Potency | 19.8170 | 2 | 24 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 21.1449 | 2 | 14 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 24.5827 | 2 | 11 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 16.1280 | 1 | 5 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 15.5865 | 1 | 8 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 19.5528 | 2 | 19 |
| BRCA1 | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 47.0063 | 1 | 12 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 41.1184 | 1 | 10 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 31.0560 | 1 | 4 |
| caspase-3 | Homo sapiens (human) | Potency | 41.1184 | 1 | 10 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 31.0560 | 1 | 4 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 29.3139 | 3 | 24 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 16.8825 | 2 | 21 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 32.1103 | 1 | 7 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 3.2957 | 1 | 2 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 21.3399 | 2 | 13 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 32.4648 | 1 | 2 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 33.6586 | 2 | 8 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 34.2580 | 2 | 8 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 52.6186 | 1 | 9 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 17.3446 | 2 | 8 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 7.9245 | 1 | 1 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 22.2320 | 1 | 16 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 34.2580 | 2 | 8 |
| chaperonin GroEL | Methanococcus maripaludis S2 | Potency | 100.0000 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 53.4364 | 2 | 23 |
| ClpP | Bacillus subtilis | Potency | 14.1254 | 1 | 1 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 9.9730 | 1 | 14 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 14.1533 | 1 | 11 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 20.5259 | 1 | 14 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 5.3004 | 1 | 31 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 7.9322 | 1 | 35 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 13.9411 | 2 | 58 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 16.6030 | 2 | 32 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 31.8670 | 1 | 12 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 4.7594 | 3 | 44 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 19.5931 | 1 | 6 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 12.7711 | 1 | 3 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 79.4328 | 1 | 1 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| DNA polymerase III, partial | Bacillus subtilis | Potency | 22.4852 | 1 | 2 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 70.5045 | 1 | 8 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 26.4194 | 1 | 5 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 0.0326 | 1 | 2 |
| endonuclease IV | Escherichia coli | Potency | 14.0463 | 1 | 10 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 25.4517 | 10 | 125 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 21.9725 | 2 | 17 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 23.3979 | 10 | 127 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 23.4168 | 2 | 42 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 20.7118 | 4 | 40 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 29.1439 | 3 | 18 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 33.6350 | 2 | 7 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 27.8229 | 1 | 23 |
| G | Vesicular stomatitis virus | Potency | 20.5259 | 1 | 14 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| GALC protein | Homo sapiens (human) | Potency | 13.7422 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 13.6126 | 1 | 30 |
| geminin | Homo sapiens (human) | Potency | 15.0120 | 4 | 58 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 12.5564 | 2 | 45 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 15.0345 | 2 | 12 |
| GLS protein | Homo sapiens (human) | Potency | 12.6801 | 2 | 13 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 13.2303 | 1 | 8 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 25.7577 | 3 | 42 |
| glucokinase regulatory protein | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 29.0729 | 1 | 13 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 3.6220 | 1 | 2 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 24.0682 | 1 | 2 |
| guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 21.2741 | 2 | 9 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 37.4394 | 2 | 8 |
| hexokinase-4 isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 12.6887 | 2 | 87 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 36.3615 | 1 | 7 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 63.5428 | 2 | 13 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 58.6544 | 1 | 2 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 20.5259 | 1 | 14 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 29.6211 | 1 | 6 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 20.2602 | 2 | 4 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 14.1078 | 2 | 32 |
| IDH1 | Homo sapiens (human) | Potency | 19.7410 | 1 | 12 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 62.2161 | 2 | 5 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 20.5259 | 1 | 28 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 5.7891 | 2 | 14 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 17.4128 | 1 | 7 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 17.4128 | 1 | 7 |
| Interferon beta | Homo sapiens (human) | Potency | 19.5998 | 3 | 34 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 14.7431 | 2 | 32 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 17.8509 | 1 | 21 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 33.7420 | 3 | 5 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 39.3639 | 3 | 3 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 37.7277 | 1 | 16 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 17.6654 | 2 | 27 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 19.7927 | 2 | 18 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 10.1484 | 2 | 35 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 23.5953 | 3 | 4 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 56.2341 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 56.2341 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 9.1201 | 1 | 10 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 7.0744 | 2 | 14 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 10.6168 | 1 | 10 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 63.3881 | 1 | 7 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 21.9096 | 4 | 27 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 24.7956 | 1 | 6 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 30.5943 | 2 | 11 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 28.4715 | 2 | 17 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 20.8114 | 1 | 2 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 26.4414 | 3 | 46 |
| Ornithine decarboxylase | Rattus norvegicus (Norway rat) | Potency | 3.9716 | 1 | 4 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 45.6752 | 1 | 6 |
| Parkin | Homo sapiens (human) | Potency | 24.2644 | 2 | 5 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 39.1143 | 2 | 7 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 20.5730 | 1 | 15 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 57.5812 | 1 | 14 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 18.6737 | 5 | 22 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 23.9828 | 5 | 25 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 61.6927 | 3 | 22 |
| PINK1 | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 13.1013 | 1 | 3 |
| polyprotein | Zika virus | Potency | 27.8229 | 1 | 23 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 11.9651 | 1 | 3 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 11.7937 | 1 | 27 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 7.1960 | 1 | 35 |
| PPM1D protein | Homo sapiens (human) | Potency | 14.8114 | 1 | 8 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 17.2855 | 3 | 21 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 50.1187 | 1 | 2 |
| progesterone receptor | Homo sapiens (human) | Potency | 34.4173 | 3 | 20 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 14.2191 | 2 | 4 |
| pyruvate kinase PKM isoform b | Homo sapiens (human) | Potency | 4.5381 | 2 | 7 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 119.0470 | 1 | 2 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 17.3631 | 2 | 32 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 67.2588 | 1 | 11 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 12.5590 | 1 | 17 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 28.3391 | 3 | 43 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 12.6452 | 4 | 29 |
| RGS12 | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 19.2051 | 4 | 25 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 22.6209 | 2 | 9 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 22.6209 | 2 | 9 |
| Smad3 | Homo sapiens (human) | Potency | 19.9051 | 1 | 8 |
| snurportin-1 | Homo sapiens (human) | Potency | 62.2161 | 2 | 5 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 24.2302 | 2 | 28 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 19.6466 | 1 | 18 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 1.3598 | 1 | 3 |
| TDP1 protein | Homo sapiens (human) | Potency | 18.2171 | 2 | 123 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 60.3740 | 1 | 2 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 24.8349 | 4 | 24 |
| Thrombopoietin | Homo sapiens (human) | Potency | 9.5180 | 2 | 18 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 19.2398 | 3 | 64 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 25.0871 | 2 | 3 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 24.8944 | 5 | 44 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 18.2362 | 2 | 6 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 6.0486 | 1 | 4 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 16.6631 | 1 | 4 |
| tumor susceptibility gene 101 protein | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| tyrosine-protein kinase Yes | Homo sapiens (human) | Potency | 34.4993 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 12.0784 | 2 | 4 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 13.1013 | 1 | 3 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 13.1013 | 1 | 3 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 40.5263 | 4 | 22 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 14.5446 | 2 | 30 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 20.3862 | 4 | 25 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 57.2140 | 1 | 10 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 29.0729 | 1 | 13 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | Homo sapiens (human) | Ki | 0.1900 | 1 | 1 |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | Ki | 0.0152 | 1 | 5 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | IC50 | 0.1374 | 16 | 18 |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | IC50 | 0.8800 | 2 | 3 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 1.3776 | 13 | 29 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 0.4297 | 90 | 122 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.3985 | 59 | 89 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | IC50 | 8.2500 | 2 | 2 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 0.9858 | 5 | 16 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Ki | 1.9813 | 6 | 7 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 4.0537 | 9 | 28 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | IC50 | 2.0484 | 6 | 6 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | IC50 | 1.3220 | 3 | 5 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | Ki | 2.6950 | 4 | 4 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | Ki | 0.8929 | 4 | 8 |
| 5-hydroxytryptamine receptor 1E | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1E | Homo sapiens (human) | Ki | 55.0000 | 2 | 2 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | IC50 | 1.3220 | 3 | 5 |
| 5-hydroxytryptamine receptor 1F | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | Ki | 0.8929 | 4 | 8 |
| 5-hydroxytryptamine receptor 2A | Bos taurus (cattle) | IC50 | 0.0090 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 0.0313 | 30 | 50 |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | IC50 | 0.0148 | 1 | 2 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 | 0.3622 | 27 | 53 |
| 5-hydroxytryptamine receptor 2A | Bos taurus (cattle) | Ki | 1.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.1103 | 87 | 167 |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | Ki | 0.0137 | 1 | 2 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 2.2143 | 72 | 118 |
| 5-hydroxytryptamine receptor 2A | Sus scrofa (pig) | Ki | 0.0300 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.1726 | 4 | 23 |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | IC50 | 0.0148 | 1 | 2 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | IC50 | 0.2008 | 20 | 38 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.1162 | 8 | 24 |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | Ki | 0.0137 | 1 | 2 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Ki | 5.3103 | 26 | 49 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 0.5974 | 10 | 29 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | IC50 | 0.2160 | 21 | 40 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 1.2379 | 43 | 113 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Ki | 3.7777 | 46 | 72 |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | IC50 | 0.0148 | 1 | 2 |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | Ki | 0.3880 | 3 | 4 |
| 5-hydroxytryptamine receptor 3A | Cavia porcellus (domestic guinea pig) | IC50 | 110.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | IC50 | 0.2379 | 12 | 12 |
| 5-hydroxytryptamine receptor 3A | Mus musculus (house mouse) | IC50 | 1.4125 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | IC50 | 1.5018 | 3 | 4 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 1.2089 | 10 | 12 |
| 5-hydroxytryptamine receptor 3A | Mus musculus (house mouse) | Ki | 3.4280 | 2 | 3 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | Ki | 2.5310 | 4 | 4 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | IC50 | 0.9420 | 3 | 3 |
| 5-hydroxytryptamine receptor 3B | Mus musculus (house mouse) | IC50 | 1.4125 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | IC50 | 1.5018 | 3 | 4 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | Ki | 0.3539 | 2 | 4 |
| 5-hydroxytryptamine receptor 3B | Mus musculus (house mouse) | Ki | 0.2520 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | Ki | 2.5311 | 4 | 4 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | Ki | 0.3539 | 2 | 4 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | Ki | 0.3539 | 2 | 4 |
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | Ki | 0.3539 | 2 | 4 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.5077 | 2 | 14 |
| 5-hydroxytryptamine receptor 4 | Homo sapiens (human) | IC50 | 0.0002 | 1 | 1 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 1.0136 | 4 | 16 |
| 5-hydroxytryptamine receptor 4 | Homo sapiens (human) | Ki | 0.0152 | 14 | 15 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | IC50 | 13.3350 | 2 | 3 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | Ki | 0.0039 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | IC50 | 2.5025 | 1 | 2 |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | Ki | 10.0121 | 4 | 11 |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | IC50 | 2.5025 | 1 | 2 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 0.1708 | 9 | 17 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | IC50 | 2.5025 | 1 | 2 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.5151 | 44 | 84 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | Ki | 0.0679 | 3 | 3 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | IC50 | 59.4667 | 1 | 6 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | IC50 | 0.0643 | 9 | 9 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | Ki | 0.0026 | 2 | 3 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.3053 | 57 | 96 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | IC50 | 2.5025 | 1 | 2 |
| 5-hydroxytryptamine receptor 7 | Mus musculus (house mouse) | Ki | 0.0630 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | Ki | 0.0389 | 6 | 23 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 1.1905 | 2 | 2 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Ki | 0.2520 | 1 | 3 |
| Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | IC50 | 1.2200 | 1 | 2 |
| Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | IC50 | 1.2200 | 1 | 2 |
| Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | IC50 | 1.2200 | 1 | 2 |
| Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | IC50 | 1.2200 | 1 | 2 |
| Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | IC50 | 0.9967 | 2 | 3 |
| Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | IC50 | 1.2200 | 1 | 2 |
| Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | IC50 | 1.2200 | 1 | 2 |
| Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | IC50 | 1.2200 | 1 | 2 |
| Albumin | Homo sapiens (human) | IC50 | 3.5000 | 1 | 2 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 0.7542 | 1 | 8 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 0.7478 | 1 | 8 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | IC50 | 0.4490 | 9 | 9 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 1.6617 | 18 | 32 |
| Alpha-1A adrenergic receptor | Bos taurus (cattle) | Ki | 0.0036 | 5 | 5 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 0.2544 | 24 | 41 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.2903 | 36 | 70 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | IC50 | 0.0110 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 1.9658 | 14 | 27 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 0.5222 | 24 | 39 |
| Alpha-1B adrenergic receptor | Mesocricetus auratus (golden hamster) | Ki | 0.0003 | 3 | 3 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.2852 | 33 | 64 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.1436 | 2 | 13 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 1.9658 | 14 | 27 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.2171 | 23 | 49 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.2484 | 37 | 70 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.5091 | 9 | 21 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.6927 | 8 | 15 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.2938 | 27 | 54 |
| Alpha-2A adrenergic receptor | Mus musculus (house mouse) | Ki | 0.0281 | 3 | 4 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.3699 | 24 | 34 |
| Alpha-2A adrenergic receptor | Sus scrofa (pig) | Ki | 0.0044 | 1 | 1 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.1562 | 7 | 19 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.7422 | 7 | 14 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.2543 | 22 | 46 |
| Alpha-2B adrenergic receptor | Mus musculus (house mouse) | Ki | 0.2225 | 4 | 5 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.3886 | 23 | 32 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 0.3244 | 9 | 21 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.7422 | 7 | 14 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.2305 | 23 | 50 |
| Alpha-2C adrenergic receptor | Mus musculus (house mouse) | Ki | 0.0281 | 3 | 4 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.4011 | 22 | 31 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | IC50 | 20.3426 | 2 | 7 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | Ki | 3.4291 | 2 | 8 |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | Ki | 0.1650 | 2 | 10 |
| AP-2 complex subunit sigma | Rattus norvegicus (Norway rat) | Ki | 0.0242 | 1 | 1 |
| Aspartate aminotransferase, cytoplasmic | Homo sapiens (human) | IC50 | 5.3900 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 11 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 3.8500 | 6 | 6 |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | IC50 | 27.4500 | 4 | 4 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Ki | 0.2000 | 1 | 1 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 0.0009 | 1 | 1 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 0.3337 | 3 | 3 |
| Beta-1 adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 17.0000 | 3 | 4 |
| Beta-1 adrenergic receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.1500 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | IC50 | 0.0005 | 1 | 1 |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 1.2200 | 1 | 2 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | Ki | 0.3336 | 3 | 3 |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 2 | 2 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | IC50 | 0.0880 | 1 | 1 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | Ki | 0.0660 | 1 | 1 |
| Beta-3 adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 2 | 2 |
| Beta-casein | Rattus norvegicus (Norway rat) | Ki | 0.0015 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 79.4986 | 6 | 36 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 106.9500 | 1 | 2 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | IC50 | 6.6000 | 1 | 1 |
| C-8 sterol isomerase | Saccharomyces cerevisiae S288C | Ki | 0.0005 | 1 | 1 |
| Calcitonin gene-related peptide type 1 receptor | Homo sapiens (human) | Ki | 0.0004 | 1 | 1 |
| Calmodulin-1 | Homo sapiens (human) | IC50 | 80.0000 | 2 | 2 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 11 |
| Cathepsin D | Bos taurus (cattle) | IC50 | 0.0600 | 1 | 1 |
| Cholecystokinin receptor type A | Cavia porcellus (domestic guinea pig) | Ki | 0.0550 | 1 | 2 |
| Cocaine esterase | Homo sapiens (human) | Ki | 0.0063 | 1 | 1 |
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 | 17.9843 | 3 | 4 |
| Cytochrome P450 2B6 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 22.0593 | 3 | 3 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 32.1975 | 3 | 4 |
| Cytochrome P450 2C9 | Homo sapiens (human) | Ki | 0.0037 | 1 | 1 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 13.7258 | 4 | 9 |
| Cytochrome P450 2D6 | Homo sapiens (human) | Ki | 0.3500 | 2 | 2 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 9.3950 | 1 | 2 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 18.5925 | 6 | 6 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 0.3751 | 4 | 15 |
| D | Bos taurus (cattle) | IC50 | 1.7624 | 3 | 5 |
| D | Mus musculus (house mouse) | IC50 | 17.8750 | 2 | 2 |
| D | Rattus norvegicus (Norway rat) | IC50 | 3.4571 | 15 | 34 |
| D | Bos taurus (cattle) | Ki | 0.4200 | 8 | 13 |
| D | Mus musculus (house mouse) | Ki | 1.7650 | 2 | 2 |
| D | Rattus norvegicus (Norway rat) | Ki | 0.6842 | 26 | 64 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 0.4790 | 2 | 12 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 0.4736 | 19 | 50 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Ki | 0.0095 | 1 | 1 |
| D(1B) dopamine receptor | Homo sapiens (human) | IC50 | 0.0050 | 1 | 1 |
| D(1B) dopamine receptor | Mus musculus (house mouse) | IC50 | 35.0000 | 1 | 1 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.4402 | 7 | 20 |
| D(1B) dopamine receptor | Homo sapiens (human) | Ki | 0.2303 | 5 | 6 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.5521 | 4 | 8 |
| D(2) dopamine receptor | Bos taurus (cattle) | IC50 | 0.9403 | 8 | 12 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 0.6010 | 21 | 38 |
| D(2) dopamine receptor | Mus musculus (house mouse) | IC50 | 7.1252 | 2 | 5 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.5072 | 43 | 97 |
| D(2) dopamine receptor | Bos taurus (cattle) | Ki | 0.1778 | 4 | 4 |
| D(2) dopamine receptor | Chlorocebus aethiops (grivet) | Ki | 0.1294 | 2 | 4 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.2367 | 176 | 272 |
| D(2) dopamine receptor | Mus musculus (house mouse) | Ki | 0.1120 | 1 | 1 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.1757 | 69 | 169 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 0.4949 | 11 | 21 |
| D(3) dopamine receptor | Mus musculus (house mouse) | IC50 | 35.0000 | 1 | 1 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.4402 | 7 | 20 |
| D(3) dopamine receptor | Chlorocebus aethiops (grivet) | Ki | 0.2345 | 1 | 2 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.4412 | 80 | 138 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.4124 | 16 | 26 |
| D(4) dopamine receptor | Homo sapiens (human) | IC50 | 0.4263 | 17 | 23 |
| D(4) dopamine receptor | Mus musculus (house mouse) | IC50 | 35.0000 | 1 | 1 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.4402 | 7 | 20 |
| D(4) dopamine receptor | Homo sapiens (human) | Ki | 0.1487 | 75 | 123 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.4106 | 7 | 11 |
| Delta-type opioid receptor | Homo sapiens (human) | IC50 | 3.7600 | 1 | 1 |
| Delta-type opioid receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 7.0700 | 2 | 3 |
| Diacylglycerol kinase alpha | Homo sapiens (human) | IC50 | 12.8500 | 2 | 2 |
| Dihydrofolate reductase | Bacillus anthracis | IC50 | 102.0000 | 1 | 1 |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | IC50 | 6.3400 | 1 | 1 |
| DNA topoisomerase 1 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| Endothelin receptor type B | Homo sapiens (human) | Ki | 0.0236 | 2 | 16 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Ki | 0.0236 | 1 | 8 |
| Endothelin-1 receptor | Homo sapiens (human) | IC50 | 0.1148 | 1 | 1 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 2.9470 | 1 | 1 |
| Estrogen receptor | Mus musculus (house mouse) | Ki | 0.0840 | 1 | 2 |
| Estrogen receptor beta | Mus musculus (house mouse) | Ki | 0.0840 | 1 | 2 |
| Fatty-acid amide hydrolase 1 | Homo sapiens (human) | IC50 | 0.8975 | 2 | 2 |
| G-protein coupled receptor | Apis mellifera (honey bee) | IC50 | 73.0000 | 1 | 1 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 7 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Ki | 2.7506 | 3 | 4 |
| Gastrin/cholecystokinin type B receptor | Mus musculus (house mouse) | Ki | 0.0136 | 1 | 4 |
| Genome polyprotein | Human rhinovirus sp. | IC50 | 140.0000 | 1 | 1 |
| Genome polyprotein | Human rhinovirus sp. | Ki | 0.1000 | 1 | 1 |
| Glucose-6-phosphate 1-dehydrogenase | Homo sapiens (human) | Ki | 497.2000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | Ki | 5.0006 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 | 2.4000 | 1 | 1 |
| Glycogen phosphorylase, brain form | Homo sapiens (human) | Ki | 24.8020 | 1 | 2 |
| Glycogen phosphorylase, muscle form | Homo sapiens (human) | Ki | 24.8020 | 1 | 2 |
| high affinity choline transporter 1 isoform a | Homo sapiens (human) | IC50 | 1.7625 | 2 | 2 |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | IC50 | 0.0970 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 0.6836 | 8 | 18 |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2384 | 3 | 9 |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.4369 | 6 | 12 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.0922 | 16 | 48 |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | Ki | 0.7033 | 2 | 3 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | IC50 | 0.8000 | 1 | 2 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 1.5886 | 1 | 9 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Ki | 1.0000 | 1 | 2 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 1.5622 | 1 | 9 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 0.9122 | 3 | 3 |
| Histamine H4 receptor | Homo sapiens (human) | Ki | 0.6443 | 4 | 4 |
| Histone-lysine N-methyltransferase SETD7 | Homo sapiens (human) | IC50 | 8.1333 | 3 | 3 |
| Histone-lysine N-methyltransferase SETD7 | Homo sapiens (human) | Ki | 15.0000 | 1 | 1 |
| Integrin alpha-4 | Homo sapiens (human) | Ki | 0.0039 | 1 | 1 |
| Integrin beta-1 | Homo sapiens (human) | Ki | 0.0039 | 1 | 1 |
| Kappa-type opioid receptor | Homo sapiens (human) | IC50 | 1.7400 | 2 | 2 |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0026 | 1 | 1 |
| Kappa-type opioid receptor | Homo sapiens (human) | Ki | 5.4980 | 2 | 2 |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 7.0700 | 2 | 3 |
| Lysosomal alpha-glucosidase | Bos taurus (cattle) | IC50 | 0.0021 | 1 | 1 |
| Lysosomal alpha-glucosidase | Bos taurus (cattle) | Ki | 0.0087 | 1 | 1 |
| Lysosomal alpha-glucosidase | Rattus norvegicus (Norway rat) | Ki | 0.0087 | 1 | 1 |
| M-phase inducer phosphatase 1 | Homo sapiens (human) | IC50 | 22.3000 | 1 | 1 |
| Mu-type opioid receptor | Homo sapiens (human) | IC50 | 1.4075 | 2 | 2 |
| Mu-type opioid receptor | Homo sapiens (human) | Ki | 3.9655 | 4 | 4 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 7.0700 | 2 | 3 |
| Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | Homo sapiens (human) | IC50 | 3.7650 | 2 | 2 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 250.8000 | 1 | 2 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 395.5000 | 1 | 2 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 127.3636 | 1 | 11 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 1.4243 | 3 | 11 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 | 0.1028 | 5 | 11 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 2.8348 | 11 | 35 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Ki | 8.0871 | 6 | 9 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 0.9100 | 1 | 7 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 | 0.1324 | 5 | 7 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 4.1038 | 5 | 18 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | Ki | 8.4385 | 7 | 9 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 12.5108 | 3 | 9 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 | 0.3252 | 6 | 9 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 4.1762 | 4 | 17 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | Ki | 13.4084 | 3 | 5 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 0.5413 | 1 | 8 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 | 0.1324 | 5 | 7 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 3.4000 | 5 | 21 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | Ki | 13.4084 | 3 | 5 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 | 0.8215 | 1 | 9 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 | 0.3534 | 6 | 8 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 3.9851 | 4 | 19 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | Ki | 13.4084 | 3 | 5 |
| Muscarinic receptor M1 | Bos taurus (cattle) | IC50 | 1.0000 | 1 | 1 |
| N-acetyltransferase Eis | Mycobacterium tuberculosis H37Rv | IC50 | 0.3900 | 1 | 1 |
| N-acetyltransferase Eis | Mycobacterium tuberculosis H37Rv | Ki | 0.3900 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Ki | 0.8318 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Ki | 0.8318 | 1 | 1 |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | IC50 | 9.6000 | 1 | 1 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | IC50 | 26.6796 | 1 | 5 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | Ki | 6.8406 | 1 | 4 |
| P2X purinoceptor 7 | Homo sapiens (human) | IC50 | 0.8300 | 1 | 1 |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | IC50 | 6.1250 | 1 | 4 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | IC50 | 2.7680 | 1 | 1 |
| Potassium channel subfamily K member 2 | Homo sapiens (human) | IC50 | 3.6500 | 1 | 2 |
| Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Potassium voltage-gated channel subfamily E member 1 | Homo sapiens (human) | IC50 | 50.1187 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 2.0671 | 43 | 123 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 9.5310 | 6 | 15 |
| Potassium voltage-gated channel subfamily KQT member 1 | Homo sapiens (human) | IC50 | 50.1187 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Ki | 0.0016 | 1 | 1 |
| Protease | Human immunodeficiency virus 1 | IC50 | 125.0000 | 1 | 1 |
| Protease | Human immunodeficiency virus 1 | Ki | 50.0500 | 2 | 2 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.6900 | 1 | 1 |
| sentrin-specific protease 8 | Homo sapiens (human) | IC50 | 12.6500 | 2 | 2 |
| Sigma intracellular receptor 2 | Homo sapiens (human) | Ki | 0.0616 | 6 | 6 |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | Ki | 0.0721 | 11 | 11 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 0.4474 | 7 | 15 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | IC50 | 0.2509 | 5 | 7 |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | Ki | 0.0049 | 37 | 37 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.2758 | 38 | 47 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.0148 | 7 | 7 |
| Sodium channel protein type 1 subunit alpha | Homo sapiens (human) | IC50 | 3.1180 | 3 | 3 |
| Sodium channel protein type 10 subunit alpha | Homo sapiens (human) | IC50 | 3.1180 | 3 | 3 |
| Sodium channel protein type 11 subunit alpha | Homo sapiens (human) | IC50 | 3.1180 | 3 | 3 |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | IC50 | 3.1180 | 3 | 3 |
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 0.3400 | 1 | 1 |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | IC50 | 3.1180 | 3 | 3 |
| Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | IC50 | 3.1180 | 3 | 3 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 21.4338 | 7 | 7 |
| Sodium channel protein type 7 subunit alpha | Homo sapiens (human) | IC50 | 3.1180 | 3 | 3 |
| Sodium channel protein type 8 subunit alpha | Homo sapiens (human) | IC50 | 3.1180 | 3 | 3 |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | IC50 | 3.1180 | 3 | 3 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 | 1.4902 | 2 | 12 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 0.5015 | 10 | 20 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 1.9905 | 2 | 4 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 0.6939 | 3 | 6 |
| Sodium-dependent noradrenaline transporter | Mus musculus (house mouse) | Ki | 0.2900 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 0.6776 | 2 | 9 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 1.8147 | 5 | 12 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 1.3230 | 3 | 10 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | IC50 | 0.8757 | 4 | 8 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 2.6488 | 10 | 23 |
| Sodium-dependent serotonin transporter | Mus musculus (house mouse) | Ki | 4.1000 | 1 | 1 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | Ki | 2.7591 | 4 | 4 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 66.7900 | 2 | 4 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 22.6000 | 1 | 2 |
| sphingosine 1-phosphate receptor 3 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Substance-K receptor | Homo sapiens (human) | IC50 | 4.0710 | 1 | 1 |
| Substance-K receptor | Homo sapiens (human) | Ki | 1.3570 | 1 | 1 |
| Synaptic vesicular amine transporter | Homo sapiens (human) | IC50 | 0.1800 | 1 | 1 |
| Synaptic vesicular amine transporter | Homo sapiens (human) | Ki | 0.5400 | 3 | 3 |
| TPA: protein transporter TIM10 | Saccharomyces cerevisiae S288C | IC50 | 37.8000 | 1 | 1 |
| Transient receptor potential cation channel subfamily V member 1 | Rattus norvegicus (Norway rat) | Ki | 0.0050 | 1 | 1 |
| Transient receptor potential cation channel subfamily V member 2 | Rattus norvegicus (Norway rat) | Ki | 0.0050 | 1 | 1 |
| Transient receptor potential cation channel subfamily V member 4 | Rattus norvegicus (Norway rat) | Ki | 0.0050 | 1 | 1 |
| Translocator protein | Rattus norvegicus (Norway rat) | Ki | 0.0043 | 1 | 1 |
| Transporter | Rattus norvegicus (Norway rat) | IC50 | 0.4273 | 2 | 6 |
| Transporter | Rattus norvegicus (Norway rat) | Ki | 3.8132 | 3 | 12 |
| Trypanothione reductase | Trypanosoma brucei brucei | IC50 | 3.4000 | 1 | 1 |
| Trypanothione reductase | Trypanosoma cruzi | IC50 | 45.1667 | 3 | 3 |
| Trypanothione reductase | Trypanosoma cruzi | Ki | 17.1200 | 5 | 5 |
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | IC50 | 0.0600 | 1 | 1 |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2100 | 1 | 1 |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | Ki | 0.2590 | 1 | 2 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | IC50 | 5.0500 | 1 | 1 |
| Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens (human) | IC50 | 2.0000 | 2 | 2 |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 | 20.0000 | 1 | 2 |
| UDP-glucuronosyltransferase 1A9 | Homo sapiens (human) | Ki | 344.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 2B7 | Homo sapiens (human) | Ki | 590.0000 | 1 | 1 |
| Vesicular acetylcholine transporter | Rattus norvegicus (Norway rat) | Ki | 3.8080 | 2 | 3 |
| Vitamin D-binding protein | Rattus norvegicus (Norway rat) | Ki | 0.0037 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Cavia porcellus (domestic guinea pig) | IC50 | 2.9120 | 3 | 5 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 48.6941 | 12 | 12 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 | 6.6558 | 9 | 9 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 | 6.6558 | 9 | 9 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 | 6.6558 | 9 | 9 |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | IC50 | 9.0000 | 1 | 1 |
| WD repeat-containing protein 48 | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| XBP1 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Zinc finger protein 664 | Cavia porcellus (domestic guinea pig) | Ki | 0.0066 | 1 | 1 |